Expression of both P1 and P2 purine receptor genes by human articular chondrocytes and profile of ligand-mediated prostaglandin E2 release

Arthritis Rheum. 1999 Feb;42(2):258-67. doi: 10.1002/1529-0131(199902)42:2<258::AID-ANR7>3.0.CO;2-O.

Abstract

Objective: To assess the expression and function of purine receptors in articular chondrocytes.

Methods: Reverse transcriptase-polymerase chain reaction (RT-PCR) was used to screen human chondrocyte RNA for expression of P1 and P2 purine receptor subtypes. Purine-stimulated prostaglandin E2 (PGE2) release from chondrocytes, untreated or treated with recombinant human interleukin-1alpha (rHuIL-1alpha), was assessed by radioimmunoassay.

Results: RT-PCR demonstrated that human articular chondrocytes transcribe messenger RNA for the P1 receptor subtypes A2a and A2b and the P2 receptor subtype P2Y2, but not for the P1 receptor subtypes A1 and A3. The P1 receptor agonists adenosine and 5'-N-ethylcarboxamidoadenosine did not change PGE2 release from chondrocytes. The P2Y2 agonists ATP and UTP stimulated a small release of PGE2 that was potentiated after pretreatment with rHuIL-1alpha. PGE2 release in response to ATP and UTP cotreatment was not additive, but release in response to coaddition of ATP and bradykinin (BK) or UTP and BK was additive, consistent with ATP and UTP competition for the same receptor site. The potentiation of PGE2 release in response to ATP and UTP after rHuIL-1alpha pretreatment was mimicked by phorbol myristate acetate.

Conclusion: Human chondrocytes express both P1 and P2 purine receptor subtypes. The function of the P1 receptor subtype is not yet known, but stimulation of the P2Y2 receptor increases IL-1-mediated PGE2 release.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenosine / pharmacology
  • Adenosine Triphosphate / pharmacology
  • Adenosine-5'-(N-ethylcarboxamide) / pharmacology
  • Aged
  • Aged, 80 and over
  • Bradykinin / pharmacology
  • Cartilage, Articular / cytology
  • Cartilage, Articular / drug effects
  • Cartilage, Articular / metabolism*
  • Chondrocytes / drug effects
  • Chondrocytes / metabolism
  • DNA Primers / chemistry
  • Dinoprostone / metabolism*
  • Drug Synergism
  • Female
  • Gene Expression
  • Humans
  • Interleukin-1 / pharmacology
  • Ligands
  • Male
  • Middle Aged
  • Purinergic P1 Receptor Agonists
  • Purinergic P2 Receptor Agonists
  • RNA, Messenger / biosynthesis
  • Receptors, Purinergic P1 / genetics*
  • Receptors, Purinergic P1 / metabolism
  • Receptors, Purinergic P2 / genetics*
  • Receptors, Purinergic P2 / metabolism
  • Recombinant Proteins / pharmacology
  • Reverse Transcriptase Polymerase Chain Reaction
  • Uridine Triphosphate / pharmacology

Substances

  • DNA Primers
  • Interleukin-1
  • Ligands
  • Purinergic P1 Receptor Agonists
  • Purinergic P2 Receptor Agonists
  • RNA, Messenger
  • Receptors, Purinergic P1
  • Receptors, Purinergic P2
  • Recombinant Proteins
  • Adenosine-5'-(N-ethylcarboxamide)
  • Adenosine Triphosphate
  • Adenosine
  • Dinoprostone
  • Bradykinin
  • Uridine Triphosphate